within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CA16_Hexobarbital;

model Hexobarbital
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.6166666666666667e-06,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.0013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0008,
    k12 = 1.3166666666666666e-06,
    k21 = 1.3166666666666666e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Hexobarbital</td></tr><tr><td>ATC code:</td><td>N05CA16</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>97</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Hexobarbital is a barbiturate derivative with sedative and hypnotic properties, formerly used as a short-acting anesthetic and in sleep disorders. Its clinical use has been largely discontinued due to safety concerns and the development of safer alternatives. It is not a currently approved or widely used medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameter estimates based on published animal and human studies, primarily from older literature. Typical values are for healthy adult humans after intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CA16 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Hexobarbital;
